Post Traumatic Stress Disorder Ptsd Pipeline Insight

DelveInsight’s, “Post-Traumatic Stress Disorder (PTSD) - Pipeline Insight, 2022,” report provides comprehensive insights about 25+ companies and 25+ pipeline drugs in Post-Traumatic Stress Disorder (PTSD) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

  • Global coverage

Post-Traumatic Stress Disorder (PTSD) Understanding

Post-Traumatic Stress Disorder (PTSD): Overview

Post-traumatic stress disorder (PTSD) is a psychiatric disorder that may occur in people who have experienced or witnessed a traumatic event such as a natural disaster, a serious accident, a terrorist act, war/combat, or rape or who have been threatened with death, sexual violence or serious injury Some experiences, like the sudden, unexpected death of a loved one, can cause PTSD. Symptoms usually begin early, within 3 months of the traumatic incident, but sometimes they begin years afterward. Symptoms must last more than a month and be severe enough to interfere with relationships or work to be considered PTSD. Treatment usually psychotherapy and counseling, medication, or a combination.

 

"Post-traumatic stress disorders - Pipeline Insight, 2022" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Post-traumatic stress disorders pipeline landscape is provided which includes the disease overview and Post-traumatic stress disorders treatment guidelines. The assessment part of the report embraces, in depth Post-traumatic stress disorders commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Post-traumatic stress disorders collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Post-traumatic stress disorders R&D. The therapies under development are focused on novel approaches to treat/improve Post-traumatic stress disorders. 

  • In February 2021, Bionomics Limited announced that it has entered into a Memorandum of Understanding with EmpathBio Inc. Under the Memorandum of Understanding, Bionomics and EmpathBio propose to collectively explore a combination drug treatment regimen with Bionomics' BNC210 and EmpathBio's 3,4-Methylenedioxymethamphetamine (MDMA) derivative EMP-01. The parties will explore whether the different mechanisms of action of EMP-01 and BNC210 may offer the potential for developing an improved treatment regimen for the treatment of Post-Traumatic Stress Disorder (PTSD).
  • In August 2021, The McQuade Center for Strategic Research and Development, LLC (MSRD), a member of the global Otsuka family of pharmaceutical companies, announced that it has entered an agreement with Aché Laboratórios Farmacêuticos S.A. (Aché), a leader in the Latin American pharmaceutical market, to co-develop a therapy with the potential to treat general anxiety disorder (GAD) and post-traumatic stress disorder (PTSD).

Post-traumatic stress disorders Emerging Drugs Chapters

This segment of the Post-traumatic stress disorders report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

 

Post-traumatic stress disorders Emerging Drugs

 

Brexpiprazole:  Otsuka Pharmaceutical Development & Commercialization

Brexpiprazole is a Dopamine D2 receptor partial agonists being developed by Otsuka Pharmaceutical Development and Commercialization in a Phase III clinical trial for Post-Traumatic stress disorder. Brexpiprazole as Combination Therapy with Sertraline is tested in the Adults with Post-traumatic Stress Disorder. This trail is expected to get completed in June 2022. 

 

NBTX-001 Xenon Inhaler: Nobilis Therapeutics

NBTX-001 is a uniquely engineered drug-device combination specifically designed to provide a differentiated pharmaceutical therapy for the treatment of PTSD. Its proprietary portable inhalation device delivers a xenon gas mixture that has an exceptional safety profile proven by decades of clinical use in general anesthesia. Xenon is a competitive NMDA receptor antagonist devoid of dissociative and habit-forming properties. XBTX-001 is under phase II/III for PTSD. 

 

BNC 210: Bionomics

BNC210 is Bionomics’ proprietary molecule in development for the treatment of Social Anxiety Disorder (SAD), Post-Traumatic Stress Disorder (PTSD) and anxiety disorders. Bionomics is conducting a phase II trial to assess the effects of BNC210 compared to placebo on PTSD symptom severity. BNC 210 blocks the alpha7 nicotinic acetylcholine receptor. BNC210 has also demonstrated a well-tolerated safety profile which indicates a potential advantage over currently available medications for the treatment of SAD, PTSD and anxiety disorders (e.g. antidepressants, benzodiazepines).  

 

Lu AG06466: H. Lundbeck A/S 

Lu AG06466 is a small molecule and a highly selective inhibitor of monoacylglycerol lipase (MAGL), the primary enzyme responsible for the degradation of the endocannabinoid ligand 2-arachidonoylglycerol (2-AG). H.Lundbeck A/S is conducting Phase I trial for Lu AG06466 after multiple doses of 30 milligrams (mg) in participants with PTSD.

Further product details are provided in the report……..

Post-traumatic stress disorders: Therapeutic Assessment

This segment of the report provides insights about the different Post-traumatic stress disorders drugs segregated based on following parameters that define the scope of the report, such as:

 

Major Players in Post-traumatic stress disorders

There are approx. 25+ key companies which are developing the therapies for Post-traumatic stress disorders. The companies which have their Post-traumatic stress disorders drug candidates in the most advanced stage, i.e. phase III include, Otsuka Pharmaceutical Development & Commercialization.

 

Phases

DelveInsight’s report covers around 25+ products under different phases of clinical development like

  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of 
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates

 

Route of Administration

Post-traumatic stress disorders pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as 

  • Inhalation
  • Inhalation/Intravenous/Oral
  • Intranasal
  • Intravenous
  • Intravenous/ Subcutaneous
  • NA
  • Oral
  • Oral/intranasal/subcutaneous
  • Parenteral
  • Subcutaneous

 

Molecule Type

Products have been categorized under various Molecule types such as

  • Antibody
  • Antisense oligonucleotides
  • Immunotherapy
  • Monoclonal antibody
  • Peptides
  • Protein
  • Recombinant protein
  • Small molecule
  • Stem Cell
  • Vaccine

 

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Post-Traumatic Stress Disorder (PTSD): Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Post-Traumatic Stress Disorder (PTSD) therapeutic drugs key players involved in developing key drugs.

 

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Post-Traumatic Stress Disorder (PTSD) drugs.

Post-Traumatic Stress Disorder (PTSD) Report Insights

  • Post-Traumatic Stress Disorder (PTSD) Pipeline Analysis
  • Therapeutic Assessment
  • Unmet Needs
  • Impact of Drugs

Post-Traumatic Stress Disorder (PTSD) Report Assessment

  • Pipeline Product Profiles
  • Therapeutic Assessment
  • Pipeline Assessment
  • Inactive drugs assessment
  • Unmet Needs

Key Questions

Current Scenario and Emerging Therapies:

  • How many companies are developing Post-Traumatic Stress Disorder (PTSD) drugs?
  • How many Post-Traumatic Stress Disorder (PTSD) drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for Post-Traumatic Stress Disorder (PTSD)?
  • What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Post-Traumatic Stress Disorder (PTSD) therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Post-Traumatic Stress Disorder (PTSD) and their status?
  • What are the key designations that have been granted to the emerging drugs?

Introduction

Executive Summary

Post-traumatic stress disorders: Overview

  • Causes
  • Mechanism of Action
  • Signs and Symptoms
  • Diagnosis
  • Disease Management

Pipeline Therapeutics

  • Comparative Analysis

Therapeutic Assessment

  • Assessment by Product Type
  • Assessment by Stage and Product Type
  • Assessment by Route of Administration
  • Assessment by Stage and Route of Administration
  • Assessment by Molecule Type
  • Assessment by Stage and Molecule Type

Post-traumatic stress disorders – DelveInsight’s Analytical Perspective

Late Stage Products (Phase III)

  • Comparative Analysis

Brexpiprazole:  Otsuka Pharmaceutical Development & Commercialization

  • Product Description
  • Research and Development
  • Product Development Activities

Drug profiles in the detailed report…..

Mid Stage Products (Phase II/III)

  • Comparative Analysis

NBTX-00: Nobilis Therapeutics

  • Product Description
  • Research and Development
  • Product Development Activities

Drug profiles in the detailed report…..

Mid Stage Products (Phase II)

  • Comparative Analysis

BNC 210: Bionomics

  • Product Description
  • Research and Development
  • Product Development Activities

Drug profiles in the detailed report…..

Early Stage Products (Phase I)

  • Comparative Analysis

Lu AG06466: H. Lundbeck A/S

  • Product Description
  • Research and Development
  • Product Development Activities

Drug profiles in the detailed report…..

Inactive Products

  • Comparative Analysis

Post-traumatic stress disorders Key Companies

Post-traumatic stress disorders Key Products

Post-traumatic stress disorders- Unmet Needs

Post-traumatic stress disorders- Market Drivers and Barriers

Post-traumatic stress disorders- Future Perspectives and Conclusion

Post-traumatic stress disorders Analyst Views

Post-traumatic stress disorders Key Companies

Appendix

List of Table

Table 1: Total Products for Post-Traumatic Stress Disorder (PTSD)

Table 2: Late Stage Products

Table 3: Mid Stage Products

Table 4: Early Stage Products

Table 5: Pre-clinical & Discovery Stage Products

Table 6: Assessment by Product Type

Table 7: Assessment by Stage and Product Type

Table 8: Assessment by Route of Administration

Table 9: Assessment by Stage and Route of Administration

Table 10: Assessment by Molecule Type

Table 11: Assessment by Stage and Molecule Type

Table 12: Inactive Products

List of Figures

Figure 1: Total Products for Post-Traumatic Stress Disorder (PTSD)

Figure 2: Late Stage Products                               

Figure 3: Mid Stage Products

Figure 4: Early Stage Products

Figure 5: Preclinical and Discovery Stage Products

Figure 6: Assessment by Product Type

Figure 7: Assessment by Stage and Product Type

Figure 8: Assessment by Route of Administration

Figure 9: Assessment by Stage and Route of Administration

Figure 10: Assessment by Molecule Type

Figure 11: Assessment by Stage and Molecule Type

Figure 12: Inactive Products    

• Aptinyx
• Jazz Pharmaceuticals
• Bionomics Limited
• Boehringer Ingelheim
• Otsuka Pharmaceutical Development & Commercialization, Inc.
• GlaxoSmithKline
• AstraZeneca
• Remedy
• H. Lundbeck A/S
• Alto Neuroscience
• Yale University
• Sage Therapeutics
• Pfizer
• Tonix Pharmaceuticals, Inc.
• Nobilis Therapeutics

 

 

Forward to Friend

Need A Quote